Nachman Norwood & Parrott Inc acquired a new position in AstraZeneca plc (NYSE:AZN) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 14,254 shares of the company’s stock, valued at approximately $541,000.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Legacy Financial Advisors Inc. lifted its position in AstraZeneca by 38.6% during the fourth quarter. Legacy Financial Advisors Inc. now owns 2,031 shares of the company’s stock valued at $77,000 after purchasing an additional 566 shares in the last quarter. Factorial Partners LLC purchased a new position in AstraZeneca during the third quarter valued at $119,000. NEXT Financial Group Inc purchased a new position in AstraZeneca during the third quarter valued at $169,000. Sit Investment Associates Inc. purchased a new position in AstraZeneca during the fourth quarter valued at $171,000. Finally, Belpointe Asset Management LLC purchased a new position in AstraZeneca during the third quarter valued at $197,000. 17.24% of the stock is owned by institutional investors.
Shares of AstraZeneca stock traded up $0.07 during trading hours on Friday, hitting $37.01. The company’s stock had a trading volume of 3,424,063 shares, compared to its average volume of 5,322,751. The company has a quick ratio of 0.66, a current ratio of 0.86 and a debt-to-equity ratio of 1.36. The company has a market capitalization of $93.57 billion, a price-to-earnings ratio of 8.65, a PEG ratio of 1.96 and a beta of 0.51. AstraZeneca plc has a 12-month low of $32.69 and a 12-month high of $41.78.
Several equities analysts have recently commented on AZN shares. Deutsche Bank restated a “buy” rating on shares of AstraZeneca in a research report on Monday, November 12th. Credit Suisse Group restated a “buy” rating on shares of AstraZeneca in a research report on Sunday, December 9th. ValuEngine upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th. SunTrust Banks started coverage on AstraZeneca in a research report on Thursday, December 13th. They issued a “buy” rating and a $48.00 price objective on the stock. Finally, Bank of America restated a “buy” rating on shares of AstraZeneca in a research report on Friday, December 14th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $45.50.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Insider Trading
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.